Breast cancer treatment: The routine use of genetic tests is not useful at present;MAMMAKARZINOM-THERAPIE: Der routinemäßige Einsatz von Gentests ist derzeit nicht sinnvoll

Deutsches Arzteblatt International

Volumn 109, Issue 42, 2012, Pages

  Scharl, Anton ^a  

^a Sprecher der Kommission Mamma der AGO EV ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER THERAPY; GENETIC SCREENING;

EID: 84898700887     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Peto R, Davies C, Godwin J et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta- analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 432-44.
2. Jänicke F, Prechtl A, Thomssen C, et al.: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.
3. Look MP, van Putten WLJ, Duffy MJ, et al.: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.
4. Hayes DF, Bast RC, Desch CE, et al.: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-66.
5. van Veer LJ 't, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
6. Paik S, Shak S, Tang G, et al.: A multigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer. NEJM 2004; 351: 2817-26.
7. Paik S, Tang G, Shak S, et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor- positive breast cancer. J Clin Oncol 2006; 24: 3726-34.
8. Albain KS, Barlow WE, Shak S, et al.: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Onco. 2010; 11: 55-65.
9. Filipits M, Rudas M, Jakesz R, et al.: A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res 2011; 17: 6012-20.
10. Denkert C, Kronenwett R, Schlake W, et al.: Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch 2012; 460: 251-9.
11. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-52.